Archives

Medical Developments International Limited (ASX:MVP) has received approval from the Medicines Control Council (MCC) in South Africa to market and sell its inhaled analgesic product, ‘Penthrox’  for pain relief from trauma and surgical procedures. The approval gives MVP’s partner in South Africa, LINK Healthcare Pte Ltd (through its wholly owned subsidiary Equity Pharmaceuticals Pty Ltd), […]

?THOROUGH QT/QTc? PENTHROX? CLINICAL TRIAL SUCCESSFULLY MEETS ALL PRIMARY AND SECONDARY OBJECTIVES

Medical Developments International Limited (ASX:MVP) is delighted to announce it has completed the
Thorough QT/QTc Clinical Trial.

20 January 2013 ASX ANOUNCEMENT RESULTS OF PIVOTAL PHASE III CLINICAL TRIAL Methoxyflurane inhalation demonstrated to be highly effective analgesic. Methoxyflurane provided clinically-significant pain reduction. Demonstrated safety of methoxyflurane for the treatment of acute pain. Primary Endpoint and Objective of the study was met. All Secondary Endpoints and Objectives were met. MVP Comment Medical Developments […]

2012 Annual General Meeting Address to Shareholders by Chairman and CEO 24 October, 2012 ADDRESS BY CHAIRMAN MR. DAVID WILLIAMS Last year I reported that our changed approach to the business allowed us to achieve a NPAT of $1.74 million for FY11. This year we recorded a record NPAT of $2.72 million. All shareholders want […]

CONTINUING GROWTH AND RECORD PROFIT Medical Developments International Limited. (MDI) (ASX:MVP) delivered a Record Net Profit After Tax of $2,704,024 for the year ended 30 June 2012, which represents a 55% increase on FY2011 ($1,743,270).  MDI finished the year with $3.5 million of cash reserves after paying $2.7 million on clinical trials and two 3 […]

Medical Developments International Limited (ASX: MVP) is delighted to confirm the 300th and final patient has been enrolled into its European Phase III trial. The trial commenced in August of 2011 and has successfully completed on time and on budget. The Phase III trial is a randomized, double blind, multi-centre, placebo controlled study to evaluate […]

Medical Developments is delighted to confirm the following results from its Interim Dividend declared on 23 February, 2012. 64% of shareholders chose to reinvest in shares in the company rather than take a cash dividend.  The remaining shareholders were paid the Internim Dividend of 3 cents on 11 April, 2012. The CEO Mr John Sharman […]